Hetero Set To Join Indian Humira Biosimilar Line-Up

 
• By Anju Ghangurde

Hetero’s biosimilar version of AbbVie's Humira (adalimumab) appears on course to a debut in India and is set to follow peers like Zydus Cadila and Torrent, signaling the build-up of more competition for the blockbuster biologic across markets.

Leadership

More from Business

More from Scrip